The 2014 ACR annual meeting: A bird's eye view of autoimmunity in 2015

Autoimmunity Reviews

Volumn 14, Issue 7, 2015, Pages 622-632

  Selmi, Carlo ^a,b   Cantarini, Luca ^c   Kivity, Shaye ^d   Dagaan, Amir ^d   Shovman, Ora ^d   Zandman Goddard, Gisele ^d,e   Perricone, Carlo ^f   Amital, Howard ^d   Toubi, Elias ^g   Shoenfeld, Yehuda ^d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d TEL AVIV UNIVERSITY   (Israel)

^e WOLFSON MEDICAL CENTER   (Israel)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

14 3 3 ; B cell depletion; BAFF; Biomarker; Calprotectin; Citrullinated peptide antibody; Citrullination; Connective tissue disease; Fibromyalgia; HMGCR; Leptin; MicroRNA; Mood disorder; Myositis; Neuropsychiatric lupus erythematosus; Prediction; Premature atherosclerosis; Sjogren; Smoking; Statins

Indexed keywords

ACETALDEHYDE; CELL NUCLEUS ANTIGEN; MALONALDEHYDE; BIOLOGICAL MARKER;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CHRONIC ARTHRITIS; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; FIBROMYALGIA; HEALTH CARE PERSONNEL; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOLOGIST; MENTAL DISEASE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SJOEGREN SYNDROME; SMOKING; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; IMMUNOLOGY; MASSACHUSETTS; ORGANIZATION; UNITED STATES;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; BIOLOGICAL MARKERS; BIOMARKERS; BOSTON; CONGRESSES AS TOPIC; HUMANS; RHEUMATIC DISEASES; SJOGREN'S SYNDROME;

EID: 84928927648     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.03.003     Document Type: Review

References (190)

1. Chora I., Guiducci S., Manetti M., Romano E., Mazzotta C., Bellando-Randone S., et al. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev 2015, 14:314-322.
2. Lanteri A., Sobanski V., Langlois C., Lefevre G., Hauspie C., Sanges S., et al. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev 2014, 13:974-980.
3. Quartuccio L., Isola M., Baldini C., Priori R., Bartoloni Bocci E., Carubbi F., et al. Biomarkers of lymphoma in Sjogren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2014, 51:75-80.
4. Terrier B., Chaara W., Dufat L., Geri G., Rosenzwajg M., Musset L., et al. Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. Autoimmun Rev 2014, 13:319-326.
5. Bonneau J., Dumestre-Perard C., Rinaudo-Gaujous M., Genin C., Sparrow M., Roblin X., et al. Systematic review: New serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev 2015, 14:231-245.
6. Maiti A.K., Nath S.K. Gene network analysis of small molecules with autoimmune disease associated genes predicts a novel strategy for drug efficacy. Autoimmun Rev 2013, 12:510-522.
7. Roberts D.M., Jones R.B., Smith R.M., Alberici F., Kumaratne D.S., Burns S., et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 2015, 57:60-65.
8. Kamal A., Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev 2014, 13:1094-1101.
9. Leardini G., Rigon C. The impact of the profile of biologics on treatment costs. Autoimmun Rev 2013, 12:842-847.
10. Olivieri I., D'Angelo S., Padula A., Leccese P., Nigro A., Palazzi C. Can we reduce the dosage of biologics in spondyloarthritis?. Autoimmun Rev 2013, 12:691-693.
11. Labrador-Horrillo M., Martinez M.A., Selva-O'Callaghan A., Trallero-Araguas E., Grau-Junyent J.M., Vilardell-Tarres M., et al. Identification of a novel myositis-associated antibody directed against cortactin. Autoimmun Rev 2014, 13:1008-1012.
12. Bodoki L., Nagy-Vincze M., Griger Z., Betteridge Z., Szollosi L., Danko K. Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014, 13:1211-1219.
13. Iaccarino L., Ghirardello A., Bettio S., Zen M., Gatto M., Punzi L., et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 2014, 48-49:122-127.
14. Kuwana M., Okazaki Y., Takeuchi T. A New multianalyte assay for detection of dermatomyositis-specific autoantibodies undetectable by commercially available immunoassays. Arthritis Rheumatol 2014, 66:S551.
15. Moghadam-Kia S., Oddis C.V., Sato S., Kuwana M., Aggarwal R. Anti-MDA5 is associated with rapidly-progressive interstitial lung disease and poor survival in U.S. Patients with amyopathic and myopathic dermatomyositis. Arthritis Rheumatol 2014, 66:S554.
16. Yaniv G., Twig G., Shor D.B., Furer A., Sherer Y., Mozes O., et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev 2015, 14:75-79.
17. Cervera R., Doria A., Amoura Z., Khamashta M., Schneider M., Guillemin F., et al. Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev 2014, 13:621-629.
18. Kuhn A., Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 2014, 48-49:14-19.
19. Lu R., Munroe M.E., Guthridge J.M., Bean K.M., Fife D., Harley J.B., et al. IFN-' (Th1), IL4 (Th2), and IL5 (Th2) Are elevated in Pre-clinical SLE and predict transition to classified disease prior to appearance of autoantibodies or clinical criteria. Arthritis Rheumatol 2014, 66:S708.
20. Duryee M.J., Klassen L.W., Schaffert C.S., Tuma D.J., Hunter C.D., Garvin R.P., et al. Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. Free Radic Biol Med 2010, 49:1480-1486.
21. Thiele G.M., Duryee M.M., Anderson D.R., Klassen L.W., Mohring S.M., Young K.A., et al. Malondialdehyde-acetaldehyde adducts (MAA) and anti-MAA antibody in rheumatoid arthritis. Arthritis Rheumatol 2014, 67:645-655.
22. Hollins H., Duryee M., Hearth-Holmes M., Mikuls T.R., Zhang Z., Su K., et al. Antibody to malondialdehyde-acetaldehyde adducts (MAA) as a Po- tential biomarker of inflammation in systemic lupus erythrematosus (SLE). Arthritis Rheumatol 2014, 66:S715.
23. Zimlichman E., Rothschild J., Shoenfeld Y., Zandman-Goddard G. Good prognosis for hospitalized SLE patients with non-related disease. Autoimmun Rev 2014, 13:1090-1093.
24. Versini M., Jeandel P.Y., Rosenthal E., Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014, 13:981-1000.
25. Arka- chaisri T., Yeo J.G., Tan J.H.T., Hoh S.F., Das L., Leong J.Y. Does anti-C1q antibody have diagnostic and prognostic roles in childhood - onset systemic lupus erythematosus?. Arthritis Rheumatol 2014, 66:S573.
26. Alunno A., Carubbi F., Bistoni O., Caterbi S., Bartoloni E., Bigerna B., et al. CD4(-)CD8(-) T-cells in primary Sjogren's syndrome: association with the extent of glandular involvement. J Autoimmun 2014, 51:38-43.
27. Barrera M.J., Bahamondes V., Sepulveda D., Quest A.F., Castro I., Cortes J., et al. Sjogren's syndrome and the epithelial target: a comprehensive review. J Autoimmun 2013, 42:7-18.
28. Burbelo P.D., Ambatipudi K., Alevizos I. Genome-wide association studies in Sjogren's syndrome: What do the genes tell us about disease pathogenesis?. Autoimmun Rev 2014, 13:756-761.
29. Kyriakidis N.C., Kapsogeorgou E.K., Tzioufas A.G. A comprehensive review of autoantibodies in primary Sjogren's syndrome: clinical phenotypes and regulatory mechanisms. J Autoimmun 2014, 51:67-74.
30. Moutsopoulos H.M. Sjogren's syndrome: a forty-year scientific journey. J Autoimmun 2014, 51:1-9.
31. Shen L., Suresh L., Lindemann M., Xuan J., Kowal P., Malyavantham K., et al. Novel autoantibodies in Sjogren's syndrome. Clin Immunol 2012, 145:251-255.
32. Vermeersch P., Bossuyt X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 2013, 12:998-1003.
33. Jasek M., Malyavantham K., Suresh L., Ambrus J.J., Pardo D. Sjö(TM), an advanced diagnostic panel for detection of Sjögren's Syndrome autoantibodies, arthritis. Rheumatol 2014, 66:S1110.
34. Avouac J., Riemekasten G., Meune C., Ruiz B., Allanore Y. Prediction of cardiac and vascular events in systemic sclerosis: input from endothelin-1 type a receptor antibodies. Arthritis Rheumatol 2014, 66:S319.
35. Hudson M., Fritzler M.J. Diagnostic criteria of systemic sclerosis. J Autoimmun 2014, 48-49:38-41.
36. Luo Y., Wang Y., Wang Q., Xiao R., Lu Q. Systemic sclerosis: genetics and epigenetics. J Autoimmun 2013, 41:161-167.
37. Sakkas L.I., Bogdanos D.P., Katsiari C., Platsoucas C.D. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. Autoimmun Rev 2014, 13:1114-1120.
38. Kourilovitch M., Galarza-Maldonado C., Ortiz-Prado E. Diagnosis and classification of rheumatoid arthritis. J Autoimmun 2014, 48-49:26-30.
39. Atzeni F., Benucci M., Salli S., Bongiovanni S., Boccassini L., Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 2013, 12:575-579.
40. Maksymowych W.P., Marotta A. 14-3-3eta: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol 2014, 32:S-35-9.
41. Van Schaardenburg D., Murphy M., Gui Y., Turk S., Maksymowych W.P., Marotta A. Change in 14-3-3' expression in early RA patients treated with dmards corresponds with change in DAS28 and good EULAR responses. Arthritis Rheumatol 2014, 66:S837.
42. Akinkuolie A.O., Buring J.E., Ridker P.M., Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc 2014, 3:e001221.
43. Ormseth M., Chung C.P., Solus J.F., Oeser A.M., Connelly M.A., Otvos J., et al. Utility of glyca, a novel inflammatory marker, for assessment of rheumatoid arthritis disease activity. Arthritis Rheumatol 2014, 66:S837.
44. Mariani A., Marsili M., Nozzi M., Faricelli R., Chiarelli F., Breda L. Serum calprotectin: review of its usefulness and validity in paediatric rheumatic diseases. Clin Exp Rheumatol 2015, 33:109-114.
45. Obry A., Lequerre T., Hardouin J., Boyer O., Fardellone P., Philippe P., et al. Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. PLoS One 2014, 9:e115800.
46. Hurnakova J., Zavada J., Hanova P., Hulejova H., Klein M., Mann H.F., et al. Serum calprotectin (S100A8/9) is an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Rheumatol 2014, 66:S58.
47. Chandran V., Thavaneswaran A., Gladman D.D. Neutrophil-lymphocyte ratio as a marker of disease activity in psoriatic arthritis. Arthritis Rheumatol 2014, 66:S704.
48. Hollan I., Meroni P.L., Ahearn J.M., Cohen Tervaert J.W., Curran S., Goodyear C.S., et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013, 12:1004-1015.
49. Rollefstad S., Ikdahl E., Hisdal J., Olsen I.C., Holme I., Hammer H.B., et al. Rosuvastatin induced carotid plaque regression in patients with inflammatory joint diseases: the RORA-as study. Arthritis Rheumatol 2014, 66:S842.
50. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
51. Draibe J.B., Pepper R.J., Merkel P.A., Salama A.D., Investigators R.-I. Serum calprotectin and disease relapse in ANCA-associated vasculitis. Arthritis Rheumatol 2014, 66:S818.
52. Rodriguez-Pla A., Warner R.L., Cuthbertson D., Carette S., Hoffman G.S., Khalidi N.A., et al. Biomarkers of disease activity in vasculitis. Arthritis Rheumatol 2014, 66:S354.
53. Goules A.V., Tzioufas A.G., Moutsopoulos H.M. Classification criteria of Sjogren's syndrome. J Autoimmun 2014, 48-49:42-45.
54. Guellec D., Cornec D., Jousse-Joulin S., Marhadour T., Marcorelles P., Pers J.O., et al. Diagnostic value of labial minor salivary gland biopsy for Sjogren's syndrome: a systematic review. Autoimmun Rev 2013, 12:416-420.
55. Jimenez S.A., Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjogren's syndrome. Autoimmun Rev 2013, 12:1046-1051.
56. Criswell L.A., Taylor K.E., Wong Q., Levine D.M., McHugh C., Laurie C., et al. Syndrome Collaborative Clinical Alliance (SICCA), The Genetic Basis of Sjögren's Syndrome (SS) Clinical Manifestations from Genome-Wide Association Analysis of Subphenotype Extremes in an International Cohort. Arthritis Rheumatol 2014, 66:S228.
57. Nocturne G., Fogel O., Nititham J., Taylor K.E., Dieude P., Dubost J.J., et al. Genetic variant and high levels of CCL11 in serum Are associated with the occurrence of lymphoma and disease activity in primary Sjögren's syndrome patients (pSS). Arthritis Rheumatol 2014, 66:S226.
58. Al-Ali S., Cockell S., Skelton A., James K., Tarn J., Young D., et al. Identification of whole blood gene expression signature in primary Sjögren's syndrome associated lymphoma. Arthritis Rheumatol 2014, 66:S1303.
59. Nocturne G., Fogel O., Dieude D., Dubost J.J., Fauchais A.L., Goeb V., et al. CXCL13 serum levels is associated with lymphoma, high B cells markers and diseases activity in primary Sjögren's syndrome patients. Arthritis Rheumatol 2014, 66:S227.
60. Ziakas P.D., Poulou L.S., Thanos L. Towards integrating positron emission tomography for work-up of patients with Sjogren's syndrome and associated lymphomas. Autoimmun Rev 2014, 13:327-329.
61. Baldini C., Pepe P., Luciano N., Ferro F., Talarico R., Grossi S., et al. A clinical prediction rule for lymphoma development in primary Sjogren's syndrome. J Rheumatol 2012, 39:804-808.
62. Alunno A., Carubbi F., Bartoloni E., Bistoni O., Caterbi S., Cipriani P., et al. Unmasking the pathogenic role of IL-17 axis in primary Sjogren's syndrome: a new era for therapeutic targeting?. Autoimmun Rev 2014, 13:1167-1173.
63. Osnes L.T., Nakken B., Bodolay E., Szodoray P. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies - novel tool for diagnostics and patient follow-up. Autoimmun Rev 2013, 12:967-971.
64. Xie B., Chen Y., Zhang S., Wu X., Zhang Z., Peng Y., et al. The expression of P2X7 receptors on peripheral blood mononuclear cells in patients with primary Sjogren's syndrome and its correlation with anxiety and depression. Clin Exp Rheumatol 2014, 32:354-360.
65. Baldini C., Rossi C., Ferro F., Santini E., Seccia V., Donati V., et al. The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjogren's syndrome. J Intern Med 2013, 274:480-489.
66. C. Baldini, E. Santini, C. Rossi, F. Sernissi, D. Martini, A. Gallo, V. Donati, N. Luciano, F. Ferro, I. Alevizos, A. Solini and S. Bombardieri, Prognostic Value of the Complex P2X7 Receptor-Inflammasome in Patients with Primary Sjögren's Syndrome at Lymphoma Risk., Arthritis Rheumatol 66:S1303.
67. Tarn J., Cockell S., Gillespie C., Al-Ali S., James K., Locke J., et al. Whole blood microRNA signature for primary Sjögren's syndrome-related lymphoma. Arthritis Rheumatol 2014, 66:S227.
68. Nezos A., Gravani F., Kapsogeorgou E.K., Voulgarelis M., Moutsopoulos H.M., Crow M.K., et al. Type I and II interferon signatures in Sjogren's syndrome: contributions in distinct clinical phenotypes and Sjogren's related lymphom-agenesis. Arthritis Rheumatol 2014, 66:S462.
69. De Carolis S., Salvi S., Botta A., Garofalo S., Garufi C., Ferrazzani S., et al. The impact of primary Sjogren's syndrome on pregnancy outcome: our series and review of the literature. Autoimmun Rev 2014, 13:103-107.
70. Castro I., Sepulveda D., Cortes J., Quest A.F., Barrera M.J., Bahamondes V., et al. Oral dryness in Sjogren's syndrome patients. Not just a question of water. Autoimmun Rev 2013, 12:567-574.
71. Cohen C., Mekinian A., Uzunhan Y., Fauchais A.L., Dhote R., Pop G., et al. 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjogren's syndrome. Autoimmun Rev 2013, 12:1109-1114.
72. Baldini C., Quartuccio L., Bartoloni E., Priori R., Carubbi F., Alunno A., et al. How does a younger Age at the onset of Sjögren's syndrome (pSS) influence the clinical presentation and the clinical course of the disease?. Arthritis Rheumatol 2014, 66:S1112.
73. Terrier B., Jasiek M., Francois H., Mesbah R., Chiche L., Fauchais A.L., et al. Renal involvement in primary Sjögren's syndrome: a multicenter French study of 95 biopsy proven cases. Arthritis Rheumatol 2014, 66:S1114.
74. Cornec D., Devauchelle-Pensec V., Mariette X., Jousse-Joulin S., Berthelot J.M., Perdriger A., et al. The Sjögren's syndrome responder index, a data-driven combined endpoint, could detect biologics efficacy. Arthritis Rheumatol 2014, 66:S1109.
75. Sciascia S., Bertolaccini M.L., Baldovino S., Roccatello D., Khamashta M.A., Sanna G. Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. Autoimmun Rev 2013, 12:426-429.
76. Sigges J., Biazar C., Landmann A., Ruland V., Patsinakidis N., Amler S., et al. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 2013, 12:694-702.
77. Toledano P., Sarbu N., Espinosa G., Bargallo N., Cervera R. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013, 12:1166-1170.
78. Wen J., Xia Y., Stock A., Michaelson J.S., Burkly L.C., Gulinello M., et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun 2013, 43:44-54.
79. Zardi E.M., Taccone A., Marigliano B., Margiotta D.P., Afeltra A. Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis. Autoimmun Rev 2014, 13:831-839.
80. Sarbu N., Alobeidi F., Toledano P., Espinosa G., Giles I., Rahman A., et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev 2015, 14:153-159.
81. Fanouriakis A., Pamfil C., Damian L.O., Felea I., Mihali E., Filipescu I., et al. Long-term efficacy and safety of pulse cyclophosphamide for neuropsychiatric systemic lupus erythematosus: a Two-centre experience. Arthritis Rheumatol 2014, 66:S1158.
82. Huang X., Magder L.S., Petri M.A. Predictors of incident seizure in systemic lupus erythematosus. Arthritis Rheumatol 2014, 2014:S1159.
83. Hanly J.G., Systemic Lupus International Collaborating Clinics, Su L., Urowitz M., Romero-Diaz J., Gordon C., Bae S.C., Bernatsky S.R., Clarke A.E., Wallace D.J., Merrill J.T., Isenberg D.A., Rahman A., Ginzler E.M., Fortin P., Gladman D.D., Sanchez-Guerrero J., Petri M.A., Bruce I., Dooley M.A., Ramsey-Goldman R., Aranow C., Alarcon G.S., Fessler B.J., Steinsson K., Nived O., Sturfelt G.K., Manzi S., Khamashta M.A., van Vollenhoven R.F., Zoma A., Ramos-Casals M., Ruiz-Irastorza G., Lim S.S., Stoll T., Inanc M., Kalunian K.C., Kamen D.L., Maddison P., Peschken C.A., Jacobsen S., Askanase A., Buyon J.P., Theriault C., Thompson K., Farewell V. Mood disorders in systemic lupus erythematousus (SLE): results from an international, inception cohort study. Arthritis Rheumatol 2014, 66:S1158.
84. Huang X., Magder L.S., Petri M.A. Prednisone is a risk factor for incident depression in systemic lupus erythematosus. Arthritis Rheumatol 2014, 66.
85. Mak A., Ho R.C.M., Tng H., Zhou J. Brain gray and white matter volume losses and their associations with glucocorticoid use in patients with newly diagnosed systemic lupus erythematosus (SLE) - a prospective MR study. Arthritis Rheumatol 2014, 66:S1163.
86. Luggen M., Gulati G., Willis R., Gonzalez E.B. Cognitive impairment in SLE and non-criterion anti-phospholipid antibodies. Arthritis Rheumatol 2014, 66:S1160.
87. Gao Y., Lo Y., Wan J., Lau E.Y.Y., Mok M.Y. Cognitive function in systemic lupus erythematosus patients with past history of neuropsychiatric manifestations: a longitudinal study. Arthritis Rheumatol 2014, 66:S1162.
88. Sinicato N.A., Lapa A.T., Postal M., Bellini B., Fernandes P.T., Marini R., et al. Metabolic syndrome features Can influenciate cognitive functions and brain lesions in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2014, 66:S1164.
89. Ichinose K., Arima K., Umeda M., Fukui S., Nishino A., Nakashima Y., et al. Predictors of therapeutic outcomes in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheumatol 2014, 66:S1160.
90. Tjensvoll A.B., Lauvsnes M.B., Hirohata S., Kvaløy J.T., Beyer M.K., Harboe E., et al. Headache in patients with systemic lupus erythematosus is associated with reduced cerebral grey matter volume, but not with measures of glial activation, anti-NR2-, or anti-P antibodies. Arthritis Rheumatol 2014, 66:S1161.
91. Sato S., Watanabe H., Asano T., Kobayashi H., Ohira H., Yashiro M. Clinical features in patients with anti-triosephosphate isomerase antibody-positive neuropsychiatric systemic lupus erythematosus. Arthritis Rheumatol 2014, 66:S1161.
92. Peres F.A., Pelicari K.O., Sinicato N.A., Postal M., Lapa A.T., Costallat L., et al. Sense of smell, anti-ribosomal P antibodies and neuropsychiatric manifestations in systemic lupus erythematosus. Arthritis Rheumatol 2014, 66:S1165.
93. Shoenfeld N., Agmon-Levin N., Flitman-Katzevman I., Paran D., Katz B.S., Kivity S., et al. The sense of smell in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1484-1487.
94. Katzav A., Ben-Ziv T., Chapman J., Blank M., Reichlin M., Shoenfeld Y. Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS -SLE (depression). J Autoimmun 2008, 31:393-398.
95. Shoenfeld Y. To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 2007, 28:165-169.
96. Strous R.D., Shoenfeld Y. To smell the immune system: olfaction, autoimmunity and brain involvement. Autoimmun Rev 2006, 6:54-60.
97. Ruiz-Irastorza G., Danza A., Perales I., Villar I., Garcia M., Delgado S., et al. Prednisone in lupus nephritis: how much is enough?. Autoimmun Rev 2014, 13:206-214.
98. Sthoeger Z., Sharabi A., Mozes E. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. J Autoimmun 2014, 54:60-71.
99. Wen J., Stock A., Wang H., Shlomchik M., Gulinello M., Putterman C. Neuropsychiatric lupus is substantially unaffected by B-cell deficiency. Arthritis Rheumatol 2014, 66:S855.
100. Mikdashi J.A., Mehta R.I., Castellani R.J. Cerebral small vessel disease in systemic lupus erythematosus: histopathological study. Arthritis Rheumatol 2014, 66:S1162.
101. Ablin J.N., Buskila D., Van Houdenhove B., Luyten P., Atzeni F., Sarzi-Puttini P. Is fibromyalgia a discrete entity?. Autoimmun Rev 2012, 11:585-588.
102. Atzeni F., Defendenti C., Ditto M.C., Batticciotto A., Ventura D., Antivalle M., et al. Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev 2014, 13:20-23.
103. Giacomelli C., Sernissi F., Sarzi-Puttini P., Di Franco M., Atzeni F., Bazzichi L. Fibromyalgia: a critical digest of the recent literature. Clin Exp Rheumatol 2013, 31:S153-S157.
104. Foerster B.R., Nascimento T.D., DeBoer M., Bender M.A., Rice I.C., Truong D.Q., et al. Excitatory and inhibitory brain metabolites as targets and predictors of effective motor cortex tDCS therapy in fibromyalgia. Arthritis Rheumatol 2015, 67:576-581.
105. Borchers A.T., Gershwin M.E. Complex regional pain syndrome: a comprehensive and critical review. Autoimmun Rev 2014, 13:242-265.
106. Goebel A., Blaes F. Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev 2013, 12:682-686.
107. Yener M., Askin A., Soyupek F., Akpinar A., Demirdas A., Sonmez S., et al. The evaluation of anxiety and depression status in spouses of sexually active reproductive women with fibromyalgia. Clin Exp Rheumatol 2015, 33:20-24.
108. Diaz-Piedra C., Di Stasi L.L., Baldwin C.M., Buela-Casal G., Catena A. Sleep disturbances of adult women suffering from fibromyalgia: A systematic review of observational studies. Sleep Med Rev 2014, 10.1016/j.smrv.2014.09.001.
109. Grodman I., Buskila D., Arnson Y., Altaman A., Amital D., Amital H. Understanding fibromyalgia and its resultant disability. Isr Med Assoc J 2011, 13:769-772.
110. Wallace D.J., Gavin I.M., Karpenko O., Barkhordar F., Gillis B.S. Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis. Rheumatol Int 2014, [Epub ahead of print].
111. Pernambuco A.P., Schetino L.P., Viana R.S., Carvalho L.S., d'Avila Reis D. The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin Exp Rheumatol 2015, 33:14-19.
112. La Rubia M., Rus A., Molina F., Del Moral M.L. Is fibromyalgia-related oxidative stress implicated in the decline of physical and mental health status?. Clin Exp Rheumatol 2013, 31:S121-S127.
113. Saeki Y., Ishihara K. Infection-immunity liaison: pathogen-driven autoimmune-mimicry (PDAIM). Autoimmun Rev 2014, 13:1064-1069.
114. Konstantinov K.N., Ulff-Moller C.J., Tzamaloukas A.H. Infections and antineutrophil cytoplasmic antibodies: Triggering mechanisms. Autoimmun Rev 2015, 14:201-203.
115. Rigante D., Castellazzi L., Bosco A., Esposito S. Is there a crossroad between infections, genetics, and Henoch-Schonlein purpura?. Autoimmun Rev 2013, 12:1016-1021.
116. Bogdanos D.P., Smyk D.S., Invernizzi P., Rigopoulou E.I., Blank M., Pouria S., et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 2013, 12:726-740.
117. Pridgen W., Duffy C., Gendreau J., Gendreau M. A Combination of Celecoxib and Famciclovir Is Efficacious in the Treatment of Fibromyalgia: Results of a Phase IIa Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Res Ther 2014, 66:S826.
118. Clair A., Emir B. The efficacy of pregabalin for treating fibromyalgia patients with moderate or severe baseline widespread pain. Arthritis Res Ther 2014, 66:S827.
119. Macfarlane G.J., Beasley M. Moderate alcohol consumption is associated with lower risk (and severity) of chronic widespread pain: results from a population-based study. Arthritis Res Ther 2014, 66:S827.
120. Chung M., Wang C. Can alcohol consumption be an alternative treatment for fibromyalgia?. Arthritis Res Ther 2013, 15:126.
121. Katz R.S., Polyak J.L. Patients Who fail biologics are more likely to have concomitant fibromyalgia. Arthritis Res Ther 2014, 66:S828.
122. Modena V., Bianchi G., Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?. Autoimmun Rev 2013, 12:835-838.
123. Jones G.T., Atzeni F., Beasley M., Fluss E., Sarzi-Puttini P., Macfarlane G.J. The prevalence of fibromyalgia in the general population: a comparison of the american college of rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol 2015, 67:568-575.
124. Shah S.N., Halpern R., Cappelleri J.C., Masters E.T., Clair A.G., Blauer-Peterson C., et al. Examination of patients newly diagnosed with fibromyalgia: Use of guideline-recommended therapies and opioids in clinical practice. Arthritis Res Ther 2014, 66:S828.
125. Cassisi G., Ceccherelli F., Atzeni F., Sarzi-Puttini P. Complementary and alternative medicine in fibromyalgia: a practical clinical debate of agreements and contrasts. Clin Exp Rheumatol 2013, 31:S134-S152.
126. Wolfe F., Walitt B.T., Rasker J., Katz R.S., Häuser W. Polysymptomatic distress categories for clinical and research use. Arthritis Res Ther 2014, 66:S395.
127. Walitt B., Nahin R., Katz R.S., Bergman M.J., Wolfe F. Development of fibromyalgia and polysymptomatic distress definitions in the national health interview survey. Arthritis Res Ther 2014, 66:S396.
128. Wolfe F., Walitt B.T., Rasker J., Katz R.S., Häuser W. Symptom increase in fibromyalgia is not consistent with the central sensitization or central hyperresponsiveness hypothesis. Arthritis Rheumatol 2014, 66:S394.
129. Ramìrez-Fernàndez M., Martinez-Martinez L.A., Vargas-Guerrero A., Martìnez-Lavìn M., Hernandez-Quintela E., Velazco-Caspia J. Small fiber neuropathy in women with fibromyalgia. A clinical pathological-correlation using confocal corneal biomicroscopy. Arthritis Rheumatol 2014, 66:S396.
130. Hildebrand B., Higgs J.B., Williamson D., Foa E., Resick P., Mintz J., et al. The fibromyalgia syndrome and widespread pain frequency in active duty U.S. service members with posttraumatic stress disorder. Arthritis Rheumatol 2014, 66:S396.
131. Brodin P., Jojic V., Gao T., Bhattacharya S., Angel C.J., Furman D., et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 2015, 160:37-47.
132. Miller F.W., Pollard K.M., Parks C.G., Germolec D.R., Leung P.S., Selmi C., et al. Criteria for environmentally associated autoimmune diseases. J Autoimmun 2012, 39:253-258.
133. Parks C.G., Miller F.W., Pollard K.M., Selmi C., Germolec D., Joyce K., et al. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int J Mol Sci 2014, 15:14269-14297.
134. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. J Autoimmun 2012, 39:249-252.
135. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun 2012, 39:272-284.
136. Miller F.W., Alfredsson L., Costenbader K.H., Kamen D.L., Nelson L.M., Norris J.M., et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun 2012, 39:259-271.
137. Chang K., Yang S.M., Kim S.H., Han K.H., Park S.J., Shin J.I. Smoking and rheumatoid arthritis. Int J Mol Sci 2014, 15:22279-22295.
138. Marie I., Gehanno J.F., Bubenheim M., Duval-Modeste A.B., Joly P., Dominique S., et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014, 13:151-156.
139. Calixto O.J., Anaya J.M. Socioeconomic status. The relationship with health and autoimmune diseases. Autoimmun Rev 2014, 13:641-654.
140. Haye Salinas M.J., Retamozo S., Alvarez A.C., Maldonado Ficco H., Dal Pra F., Citera G., et al. Effects of cigarette smoking on early arthritis: a cross-sectional study-data from the Argentine Consortium for Early Arthritis (CONAART). Rheumatol Int 2014, [Epub ahead of print].
141. Criswell L.A., Merlino L.A., Cerhan J.R., Mikuls T.R., Mudano A.S., Burma M., et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med 2002, 112:465-471.
142. Padyukov L., Silva C., Stolt P., Alfredsson L., Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004, 50:3085-3092.
143. Costenbader K.H., Feskanich D., Mandl L.A., Karlson E.W. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006, 119:503 e1-9.
144. Sugiyama D., Nishimura K., Tamaki K., Tsuji G., Nakazawa T., Morinobu A., et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010, 69:70-81.
145. Di Giuseppe D., Discacciati A., Orsini N., Wolk A. Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. Arthritis Res Ther 2014, 16:R61.
146. Krishnan E., Sokka T., Hannonen P. Smoking-gender interaction and risk for rheumatoid arthritis. Arthritis Res Ther 2003, 5:R158-R162.
147. Jiang X., Bengtsson C., Källberg H., Klareskog L., Alfredsson L. Amount of smoking, duration of smoking cessation, and their interaction with silica exposure in the risk of rheumatoid arthritis: results from the Swedish epidemiological investigation of rheumatoid arthritis study. Arthritis Rheum 2014, 66:S1262.
148. Gomez-Puerta J.A., Gedmintas L., Costenbader K.H. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev 2013, 12:1129-1135.
149. Sokolove J., Sayles H., Wagner C., Lahey L.J., Thiele G.M., Robinson W.H., et al. Smoking status is associated with inflammatory cytokine profile and disease activity: decreased inflammation and disease improvement with smoking cessation?. Arthritis Rheum 2014, 66:S146.
150. Turesson C., Book C., Bergström U., Jacobsson L., Saxne T. Increasing cartilage turnover in smokers developing rheumatoid arthritis is associated with high disease activity in early disease. Arthritis Rheumatol 2014, 66:S186.
151. Chatzidionysiou K., Lie E., Nasonov E., Lukina G., Hetland M.L., Hauge E., et al. Smoking and response to rituximab in anti-CCP positive and negative rheumatoid arthritis - results from an international European collaboration. Arthritis Rheumatol 2014, 66:S1104.
152. Dimitroulas T., Nikas S.N., Trontzas P., Kitas G.D. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev 2013, 12:958-966.
153. Bokarewa M., Erlandsson M., S.S.T., Ioan-Fascinay A., Doria Medina R. Smoking functions as a negative regulator of IGF-1 levels and adipokine network in patients with rheumatoid arthritis. Arthritis Rheumatol 2014, 66:S185.
154. Cutolo M., Nadler S.G. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 2013, 12:758-767.
155. Lee E.Y., Lee Z.H., Song Y.W. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 2013, 12:554-557.
156. Carvalheiro H., da Silva J.A., Souto-Carneiro M.M. Potential roles for CD8(+) T cells in rheumatoid arthritis. Autoimmun Rev 2013, 12:401-409.
157. Joseph R.M., Movahedi M., Symmons D.P. Smoking-related mortality in rheumatoid arthritis. A retrospective cohort study using electronic medical records 2014.
158. Aimer P., Treharne G., Stebbings S., Frampton C., Cameron V., K.S., et al. A pilot randomized controlled trial of a tailored smoking cessation intervention for rheumatoid arthritis patients. Arthritis Rheumatol 2014, 66:S1035.
159. Dean L.E., Atzeni F., Ratz T., MacDonald A.G., Sturrock R.D., Hunter J., et al. Evaluation of clinical parameters and quality of life in smokers with ankylosing spondylitis: results from the Scotland registry for ankylosing spondylitis. Arthritis Rheumatol 2014, 66:S247.
160. Sakellariou G., Gerou S., Oikonomou D., Sayegh F. Association of smoking with acute phase reactants and molecules involved in bone formation in patients with ankylosing spondylitis. Arthritis Rheumatol 2014, 66:S1130.
161. Maldonado-Ficco H., Thavaneswaran A., Chandran V., Gladman D.D. Joint damage is Not associated with smoking status in patients with psoriatic arthritis. Arthritis Rheumatol 2014, 66:S693.
162. Dellyes A., Lafforgue P., Pradel V., Pham T. Smoking is Not associated with response to TNF blockers in patients with axial spondyloarthritis. Arthritis Rheumatol 2014, 66.
163. Atzeni F., Talotta R., Salaffi F., Cassinotti A., Varisco V., Battellino M., et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013, 12:703-708.
164. Solomon G. Immunogenicity - implications for rheumatoid arthritis treatment. Bull Hosp Jt Dis 2013, 71:200-203. [2013].
165. Fabbroni M., Cantarini L., Caso F., Costa L., Pagano V.A., Frediani B., et al. Drug retention rates and treatment discontinuation among anti-TNF-alpha agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm 2014, 2014:862969.
166. Selmi C., Ceribelli A., Naguwa S.M., Cantarini L., Shoenfeld Y. Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf 2015, 14:389-399.
167. Bao Y., Cao X. The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review. J Autoimmun 2014, 55:10-23.
168. Carter L.M., Isenberg D.A., Ehrenstein M.R. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013, 65:2672-2679.
169. Kessel A., Haj T., Peri R., Snir A., Melamed D., Sabo E., et al. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 2012, 11:670-677.
170. Fleischer S., Giesecke C., Mei H., Lipsky P.E., Daridon C., Dörner T. A novel CD27(-) spleen tyrosine kinase (Syk) bright memory B-cell subset is expanded in SLE. Arthritis Rheumatol 2014, 66:S858.
171. Fleischer S.J., Giesecke C., Mei H.E., Lipsky P.E., Daridon C., Dorner T. Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus. Arthritis Rheumatol 2014, 66:3424-3435.
172. Fujii H., Machiyama T., Akita K., Kamogawa Y., Watanabe R., Fujita Y., et al. Circulating CD19 CD38 CD43 B cell subset in SLE patients have more cell cycle related genes than healthy controls. Arthritis Rheumatol 2014, 66:S858.
173. Li Q., Dashwood W.M., Zhong X., Al-Fageeh M., Dashwood R.H. Cloning of the rat beta-catenin gene (Ctnnb1) promoter and its functional analysis compared with the Catnb and CTNNB1 promoters. Genomics 2004, 83:231-242.
174. Ducreux J., Nieuwland S., Houssiau F.A., Lauwerys B.R. Increased CD95 (Fas) expression on naive B cells is associated with a switch to double negative and plasma cells in the peripheral blood, and correlates with disease activity in systemic lupus erythematosus. Arthritis Rheumatol 2014, 66:S716.
175. Kusner L.L., Ciesielski M.J., Marx A., Kaminski H.J., Fenstermaker R.A. Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study. PLoS One 2014, 9:e102231.
176. Lutalo P.M.K., D'Cruz D.P., Spencer J. Alterations in B cell subsets and BAFF levels in autoimmune rheumatic diseases treated with B cell depletion therapy: rituximab. Arthritis Rheumatol 2014, 66:S1178.
177. Sim J.H., Kim H.R., Chang S.H., Kim I.J., Lipsky P.E., Lee J. Autoregulatory function of IL-10 producing pre-Naive B cells is defective in systemic lupus erythematosus. Arthritis Rheumatol 2014, 66:S1177.
178. Matsumoto M., Baba A., Yokota T., Nishikawa H., Ohkawa Y., Kayama H., et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity 2014, 41:1040-1051.
179. Fleischer V., Sieber J., Fleischer S.J., Shock A., Heine G., Daridon C., et al. Targeting CD22 with epratuzumab impacts cytokine production by B cells. Arthritis Rheumatol 2014, 66:S856.
180. Pongratz G., Wiest C., Melzer M., Strraub R. '2 adrenoceptor signal is augmented in B cells in the course of arthritis to increase IL-10. Arthritis Rheumatol 2014, 66:S443.
181. Nijhuis L.E., Olivier B.J., Dhawan S., Hilbers F.W., Boon L., Wolkers M.C., et al. Adrenergic beta2 receptor activation stimulates anti-inflammatory properties of dendritic cells in vitro. PLoS One 2014, 9:e85086.
182. Singh R.P., Massachi I., Manickavel S., Singh S., Rao N.P., Hasan S., et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev 2013, 12:1160-1165.
183. Zhao M., Liu S., Luo S., Wu H., Tang M., Cheng W., et al. DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. J Autoimmun 2014, 54:127-136.
184. Lega J.C., Fabien N., Reynaud Q., Durieu I., Durupt S., Dutertre M., et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014, 13:883-891.
185. Caetano-Lopes J., Rodrigues A., Lopes A., Vale A.C., Pitts-Kiefer M.A., Vidal B., et al. Rheumatoid arthritis bone fragility is associated with upregulation of IL17 and DKK1 gene expression. Clin Rev Allergy Immunol 2014, 47:38-45.
186. Selmi C., Shoenfeld Y. Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting. BMC Med 2014, 12:50.
187. Perricone C., Valesini G. Discovering the pathogenesis of autoimmune diseases at the 9th International Congress of Autoimmunity, Nice, France, 2014. Immunol Res 2014, 60:253-256.
188. Perricone C., Perricone R. Autoimmunity cutting edge at the 21st century. Representation of the 9th International Congress of Autoimmunity, Nice, France 2014. Autoimmun Rev 2014, 13:1079-1081.
189. Rosenthal E., Versini M., Jeandel P.Y., Shoenfeld Y. Introduction to the special issue on the 9th International Congress on Autoimmunity. Immunol Res 2014, 60:153-155.
190. Selmi C. Hot topics in autoimmune diseases: perspectives from the 2013 Asian Congress of Autoimmunity. Autoimmun Rev 2014, 13:781-787.